{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:41:33Z","timestamp":1790764893736,"version":"4.1.0"},"reference-count":65,"publisher":"Informa UK Limited","issue":"22","license":[{"start":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T00:00:00Z","timestamp":1718668800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncology"],"published-print":{"date-parts":[[2024,7,11]]},"DOI":"10.1080\/14796694.2024.2357537","type":"journal-article","created":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T10:54:14Z","timestamp":1725533654000},"page":"1601-1615","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["End\u00a0points in clinical trials in diffuse large B-cell lymphoma: time for more dialogue?"],"prefix":"10.1080","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-6894-9847","authenticated-orcid":false,"given":"Evgeny","family":"Degtyarev","sequence":"first","affiliation":[{"name":"Novartis Pharma, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natacha","family":"Bola\u00f1os","sequence":"additional","affiliation":[{"name":"Lymphoma Coalition, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D","family":"Brody","sequence":"additional","affiliation":[{"name":"Hematology &amp; Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aby","family":"Buchbinder","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals, East Hanover, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Buyse","sequence":"additional","affiliation":[{"name":"International Drug Development Institute (IDDI), Louvain-la-Neuve, Belgium"},{"name":"Interuniversity Institute for Biostatistics &amp; Statistical Bioinformatics (I-BioStat), Hasselt University, Diepenbeek, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Fuchs","sequence":"additional","affiliation":[{"name":"Novartis Pharma, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Halabi","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, North Carolina, USA"},{"name":"Department of Biostatistics &amp; Bioinformatics, Duke University School of Medicine, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Hemmings","sequence":"additional","affiliation":[{"name":"CONSILIUM Salmonson &amp; Hemmings, Woking, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisha","family":"Masood","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals, East Hanover, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Newsome","sequence":"additional","affiliation":[{"name":"Novartis Pharma, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Saxton","sequence":"additional","affiliation":[{"name":"Cancer Support Community, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorna","family":"Warwick","sequence":"additional","affiliation":[{"name":"Lymphoma Coalition, Management, Mississauga ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel A","family":"Yateman","sequence":"additional","affiliation":[{"name":"Novartis Pharma, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Zuber","sequence":"additional","affiliation":[{"name":"Novartis Pharma, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,6,18]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00200-5"},{"key":"e_1_3_6_4_1","unstructured":"FDA Guidance for Industry. Clinical trial endpoints for the approval of cancer drugs and biologics. December 2018. Available from: www.fda.gov\/media\/71195\/download"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/2191-1991-4-2"},{"key":"e_1_3_6_6_1","unstructured":"ICH Harmonised Guideline. E8(R1) General considerations for clinical studies. [updated 2021 Oct 06]. Available from: www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/ich-guideline-e8-r1-general-considerations-clinical-studies_en.pdf"},{"key":"e_1_3_6_7_1","unstructured":"ICH Harmonised Guideline. E9(R1) Addendum on estimands and sensitivity analysis in clinical trials. [updated 2019 Nov 20]. Available from: https:\/\/database.ich.org\/sites\/default\/files\/E9-R1_Step4_Guideline_2019_1203.pdf"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/PO.18.00381"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-276246"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02403"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01994"},{"key":"#cr-split#-e_1_3_6_13_1.1","unstructured":"ClinicalTrials.gov. Study to compare axicabtagene ciloleucel with standard of care therapy as first-line treatment in participants with high-risk large B-cell lymphoma (ZUMA-23). [Last updated: 2024 Feb 22"},{"key":"#cr-split#-e_1_3_6_13_1.2","unstructured":"accessed: 2024 Feb 23]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05605899"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.100818"},{"key":"#cr-split#-e_1_3_6_15_1.1","unstructured":"ClinicalTrials.gov. A study to evaluate change in disease activity of subcutaneous (sc) epcoritamab combined with intravenous and oral rituximab cyclophosphamide doxorubicin hydrochloride vincristine and prednisone (R-CHOP) or R-CHOP in adult participants with newly diagnosed diffuse large B-cell lymphoma (DLBCL) (EPCORE DLBCL-2). [Last updated: 2024 Feb 23"},{"key":"#cr-split#-e_1_3_6_15_1.2","unstructured":"accessed: 2024 Feb 23]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05578976"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.3402"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01366"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115304"},{"key":"#cr-split#-e_1_3_6_19_1.1","unstructured":"ClinicalTrials.gov. A randomized multicenter Phase III trial comparing treatment with R-mini-CHOP with R-mini-CHP + polatuzumab vedotin in patients with diffuse large cell B cell lymphoma (POLAR BEAR). [Last updated: 2024 Feb 13"},{"key":"#cr-split#-e_1_3_6_19_1.2","unstructured":"accessed: 2024 Feb 23]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04332822"},{"key":"#cr-split#-e_1_3_6_20_1.1","unstructured":"ClinicalTrials.gov. Tafasitamab + lenalidomide + R-CHOP versus R-CHOP in newly diagnosed high-intermediate and high risk DLBCL patients (frontMIND). [Last updated: 2023 Nov 29"},{"key":"#cr-split#-e_1_3_6_20_1.2","unstructured":"accessed: 2024 Feb 23]. Available from: www.clinicaltrials.gov\/ct2\/show\/NCT04824092"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116596"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116133"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00662-6"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2016-0137"},{"key":"#cr-split#-e_1_3_6_25_1.1","unstructured":"ClinicalTrials.gov. Study to evaluate loncastuximab tesirine with rituximab versus immunochemotherapy in participants with relapsed or refractory diffuse large B-cell lymphoma (LOTIS 5). [Last updated: 2024 Jan 24"},{"key":"#cr-split#-e_1_3_6_25_1.2","unstructured":"accessed: 2024 Feb 23]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04384484"},{"key":"#cr-split#-e_1_3_6_26_1.1","unstructured":"ClinicalTrials.gov. A study evaluating efficacy and safety of mosunetuzumab in combination with polatuzumab vedotin compared to rituximab in combination with gemcitabine plus oxaliplatin in participants with relapsed or refractory aggressive B-cell non-hodgkin's lymphoma (SUNMO). [Last updated: 2024 Jan 31"},{"key":"#cr-split#-e_1_3_6_26_1.2","unstructured":"accessed: 2024 Feb 23]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05171647"},{"key":"#cr-split#-e_1_3_6_27_1.1","unstructured":"ClinicalTrials.gov. A study of rituximab-gemcitabine-dexamethasone-platinum (R-GDP) with or without selinexor in patients with relapsed\/refractory diffuse large B-cell lymphoma. [Last updated: 2023 Oct 03"},{"key":"#cr-split#-e_1_3_6_27_1.2","unstructured":"accessed: 2024 Feb 23]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04442022"},{"key":"#cr-split#-e_1_3_6_28_1.1","unstructured":"ClinicalTrials.gov. A trial to evaluate the efficacy and safety of tafasitamab with bendamustine (BEN) versus rituximab (RTX) with BEN in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (B-MIND). [Last updated: 2022 Aug 02"},{"key":"#cr-split#-e_1_3_6_28_1.2","unstructured":"accessed: 2024 Feb 23] https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02763319"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14820"},{"key":"#cr-split#-e_1_3_6_30_1.1","unstructured":"ClinicalTrials.gov. A Phase III trial of epcoritamab vs investigator's choice chemotherapy in R\/R DLBCL (EPCORE DLBCL-1). [Last updated: 2024 Feb 06"},{"key":"#cr-split#-e_1_3_6_30_1.2","unstructured":"accessed: 2024 Feb 23]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04628494"},{"key":"#cr-split#-e_1_3_6_31_1.1","unstructured":"ClinicalTrials.gov. A study to evaluate the safety and efficacy of polatuzumab vedotin in combination with rituximab gemcitabine and oxaliplatin compared to rituximab gemcitabine and oxaliplatin alone in participants with relapsed or refractory diffuse large B-cell lymphoma (POLARGO). [Last updated: 2023 Dec 14"},{"key":"#cr-split#-e_1_3_6_31_1.2","unstructured":"accessed: 2024 Feb 23]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04182204"},{"key":"#cr-split#-e_1_3_6_32_1.1","unstructured":"ClinicalTrials.gov. A Phase III study evaluating glofitamab in combination with gemcitabine + oxaliplatin vs rituximab in combination with gemcitabine + oxaliplatin in participants with relapsed\/refractory diffuse large B-cell lymphoma. [Last updated: 2024 Feb 13"},{"key":"#cr-split#-e_1_3_6_32_1.2","unstructured":"accessed: 2024 Feb 23]. Available from: www.clinicaltrials.gov\/ct2\/show\/NCT04408638"},{"key":"#cr-split#-e_1_3_6_33_1.1","unstructured":"ClinicalTrials.gov. Polatuzumab vedotin plus rituximab ifosfamide carboplatin and etoposide (Pola-R-ICE) versus R-ICE alone in second line treatment of diffuse large B-cell lymphoma (DLBCL). [Last updated: 2023 Oct 12"},{"key":"#cr-split#-e_1_3_6_33_1.2","unstructured":"accessed: 2024 Feb 23]. Available from: www.clinicaltrials.gov\/ct2\/show\/NCT04833114"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/pst.2158"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-718528"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2020200443"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0057"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-769620"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00473-3"},{"key":"e_1_3_6_41_1","unstructured":"FDA Guidance for Industry. Acute Myeloid Leukemia: Developing Drugs and Biological Products for Treatment. October 2022. Available from: www.fda.gov\/media\/162362\/download"},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.13-S2-19"},{"key":"e_1_3_6_43_1","unstructured":"Clinical Review and Evaluation \u2013 YESCARTA. 2022 Apr 01. Available from: www.fda.gov\/media\/157687\/download"},{"key":"e_1_3_6_44_1","unstructured":"US Package Insert \u2013 YESCARTA. [revised: Dec 2023]. Available from: www.fda.gov\/media\/108377\/download"},{"key":"e_1_3_6_45_1","unstructured":"Riedell PA Brower J Nastoupil LJ et al. A multicenter retrospective analysis of outcomes and toxicities with commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed\/refractory aggressive B-cell lymphomas. Oral presentation 52. Presented at: Orlando FL: 2020 TCT; February 19\u201323 2020."},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-147369"},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-154037"},{"key":"e_1_3_6_48_1","unstructured":"Quality of Life of Cancer Patients - EORTC QLQ-C30. Available from: https:\/\/qol.eortc.org\/questionnaire\/eortc-qlq-c30\/"},{"key":"e_1_3_6_49_1","unstructured":"FACT-Lym (facit.org). Functional Assessment of Cancer Therapy \u2013 Lymphoma. Available from: www.facit.org\/measures\/FACT-Lym"},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00021-3"},{"key":"e_1_3_6_51_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-020-00218-5"},{"key":"e_1_3_6_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/pst.1917"},{"key":"e_1_3_6_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021\u2013151611"},{"key":"e_1_3_6_54_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djm024"},{"key":"e_1_3_6_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/pst.2079"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2024.2357537","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T11:57:09Z","timestamp":1727783829000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14796694.2024.2357537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,18]]},"references-count":65,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2024,7,11]]}},"alternative-id":["10.1080\/14796694.2024.2357537"],"URL":"https:\/\/doi.org\/10.1080\/14796694.2024.2357537","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,18]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-10-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}